Clinical trials: PEG-rhG-CSF
Preeclampsia
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
This is an open-label, single-arm, Phase Ⅰa clinical study designed to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of multiple doses of Telpegfilgrastim Injection in non-pregnant…
- Trial name
- NCT06924385
- Testing
- Telpegfilgrastim Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
PD-1 Inhibitor, G-CSF
PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure
Recurrence and metastasis are the main causes of treatment failure of NPC. Preliminary clinical studies have found that the overall response rate of PD-1 inhibitors in treating ≥2 line R/M NPC is about 25%.
- Trial name
- NCT05222035
- Testing
- Camrelizumab, G-CSF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Chemotherapy-induced Neutropenia
Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
This prospective, real-world observational registry study will evaluate the effectiveness and safety of mecapegfilgrastim for the prevention of chemotherapy-induced neutropenia in patients with advanced breast cancer receiving…
- Trial name
- NCT07899099
- Testing
- No Prophylactic G-CSF, Short-acting G-CSF, Long-acting G-CSF
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zheng Yabing
PEG-rhG-CSF, Pancreatic Cancer
PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer
A prospective, open, single-arm clinical study to evaluate the efficacy and safety of jinyouli（PEG-rhG-CSF） in the first-line treatment of advanced pancreatic cancer with nab-paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04518800
- Testing
- Jin Youli(PEG-rhG-CSF)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Advanced Pancreatic Cancer
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04239001
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Hematological Malignancy
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) on hematopoietic stem cell mobilization in poor…
- Trial name
- NCT05510089
- Testing
- Etoposide, Cytarabine, PEG-rhG-CSF
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Breast Cancer
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
The purpose of this study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy
- Trial name
- NCT02805153
- Testing
- PEG-rhG-CSF, rhG-CSF
- Volunteers
- 215 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Lymphoma,Non-Hodgkin
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Trial name
- NCT02996617
- Testing
- rhG-CSF regimen, Pegylated rhG-CSF regimen
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shandong Provincial Hospital
Breast Cancer, Neutropenia
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Conditions
- Breast Cancer, Neutropenia, Febrile Neutropenia
- Trial name
- NCT02119715
- Testing
- Pegylated rhG-CSF 100μg/kg, Pegylated rhG-CSF:150 μg/kg, rhG-CSF 5 μg/kg/day
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
GC/GEJC
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
This study is a prospective, randomized ，multicencter, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery.
- Trial name
- NCT06684158
- Testing
- Mecapegfilgrastim, Adebrelimab, Docetaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Multiple Myeloma, Hematopoietic Stem Cell Mobilization
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem…
- Trial name
- NCT06520176
- Testing
- Etoposide, Cytarabine, Pegfilgrastim
- Where
- 16 sites in China
- Volunteers
- 99 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Breast Cancer, Neutropenia
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
This is a prospective, single-center, single-arm clinical study, to evaluate the clinical efficacy, safety and tolerance of patients with early breast cancer receiving ddEC adjuvant chemotherapy, accepting PEG-rhG-CSF as primary…
- Trial name
- NCT04009941
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Peking University
Mammary Cancer, Lymphoma
The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy
The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.
- Conditions
- Mammary Cancer, Lymphoma, Bone Tumour, Gynecological Tumors
- Trial name
- NCT02905916
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 217 people
- Sponsor
- Peking University
Breast Cancer
The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia
The purpose of this study is to evaluate the safety and efficacy of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia
- Trial name
- NCT02761460
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 338 people
- Sponsor
- wang shusen
Breastcancer
The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer who were treated with intensive chemotherapy for prevention of neutrophil reduction.
- Trial name
- NCT02944604
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University
Biliary Tract Neoplasms
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
The purpose of this study is to assess the safety and efficacy of Gemcitabine/cisplatin combined with Adebrelimab and Mecapegfilgrastim in neoadjuvant treatment of potentially resectable Biliary Tract Neoplasms.
- Trial name
- Modified (NCT06037655)
- Testing
- Total Neoadjuvant Treatment
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Malignant Solid Tumors
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lung cancer,head and neck cancer,colorectal cancer,and ovarian cancer receiving multi-cycle chemotherapy.
- Trial name
- NCT02805166
- Testing
- PEG-rhG-CSF
- Volunteers
- 420 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Granulocyte Colony-stimulating Factor, Stem Cell Mobilization
A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF
Have a comparison between pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) for difference in efficacy of hematopoietic…
- Trial name
- NCT05409547
- Testing
- PEG-rhG-CSF
- Volunteers
- 80 people
- Sponsor
- Ning Huang
Diabetes Mellitus, Type 1
ATG-GCSF in New Onset Type 1 Diabetes
This is a three-arm, 1:1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects…
- Trial name
- ATG-GCSF (NCT02215200)
- Testing
- Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF)
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.
- Conditions
- Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor, Cost-Benefit Analysis
- Trial name
- NCT04083079
- Testing
- PEG-rhG-CSF, rhG-CSF
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Ruijin Hospital